secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001171843-24-006057
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction
--------------------------------------------------------------------------

- Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.
- Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.
- MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.
- CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.
- COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/0001171843-24-006057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324006057/f8k_110624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer